Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign.
The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies.


CONCLUSIONS
While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed.
Chiappini
Elena
E
Department of Sciences for Woman and Child's Health, University of Florence, Viale Pieraccini, Florence, Italy.
Venturini
Elisabetta
E
Bonsignori
Francesca
F
Galli
Luisa
L
de Martino
Maurizio
M
D002648:Child; D005060:Europe; D006801:Humans; D007115:Immunization Schedule; D032541:Mass Vaccination; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage*
D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine